Marker Therapeutics (MRKR) Competitors $1.01 -0.09 (-8.09%) Closing price 04/4/2025 03:58 PM EasternExtended Trading$1.01 0.00 (-0.10%) As of 04/4/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRKR vs. KPTI, IMRX, ONCY, CTMX, PDSB, KRON, VRPX, XFOR, CTOR, and VNRXShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Karyopharm Therapeutics (KPTI), Immuneering (IMRX), Oncolytics Biotech (ONCY), CytomX Therapeutics (CTMX), PDS Biotechnology (PDSB), Kronos Bio (KRON), Virpax Pharmaceuticals (VRPX), X4 Pharmaceuticals (XFOR), Citius Oncology (CTOR), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Karyopharm Therapeutics Immuneering Oncolytics Biotech CytomX Therapeutics PDS Biotechnology Kronos Bio Virpax Pharmaceuticals X4 Pharmaceuticals Citius Oncology VolitionRx Karyopharm Therapeutics (NASDAQ:KPTI) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Do analysts rate KPTI or MRKR? Karyopharm Therapeutics presently has a consensus target price of $57.50, suggesting a potential upside of 1,389.64%. Marker Therapeutics has a consensus target price of $13.17, suggesting a potential upside of 1,202.34%. Given Karyopharm Therapeutics' higher possible upside, equities analysts clearly believe Karyopharm Therapeutics is more favorable than Marker Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Does the media prefer KPTI or MRKR? In the previous week, Marker Therapeutics had 14 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 16 mentions for Marker Therapeutics and 2 mentions for Karyopharm Therapeutics. Marker Therapeutics' average media sentiment score of 0.42 beat Karyopharm Therapeutics' score of 0.34 indicating that Marker Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Marker Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, KPTI or MRKR? Marker Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.22-$143.10M-$15.29-0.25Marker Therapeutics$3.31M3.27-$8.24M-$1.20-0.84 Is KPTI or MRKR more profitable? Karyopharm Therapeutics has a net margin of -52.62% compared to Marker Therapeutics' net margin of -179.74%. Karyopharm Therapeutics' return on equity of 0.00% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-52.62% N/A -39.58% Marker Therapeutics -179.74%-89.63%-71.62% Which has more volatility & risk, KPTI or MRKR? Karyopharm Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Do insiders and institutionals have more ownership in KPTI or MRKR? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 2.8% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in KPTI or MRKR? Karyopharm Therapeutics received 466 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 72.42% of users gave Karyopharm Therapeutics an outperform vote while only 64.66% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformKaryopharm TherapeuticsOutperform Votes54172.42% Underperform Votes20627.58% Marker TherapeuticsOutperform Votes7564.66% Underperform Votes4135.34% SummaryMarker Therapeutics beats Karyopharm Therapeutics on 10 of the 19 factors compared between the two stocks. Remove Ads Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.83M$6.35B$5.26B$7.12BDividend YieldN/A2.85%4.89%4.08%P/E Ratio-0.846.8321.3817.50Price / Sales3.27187.43355.0687.33Price / CashN/A65.6738.1834.64Price / Book0.645.576.233.79Net Income-$8.24M$141.89M$3.21B$247.48M7 Day Performance-20.39%-11.51%-8.47%-6.79%1 Month Performance-45.05%-16.59%-4.87%-11.53%1 Year Performance-78.72%-18.14%2.54%-7.82% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics3.8169 of 5 stars$1.01-8.1%$13.17+1,202.3%-79.3%$10.83M$3.31M-0.8460Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownKPTIKaryopharm Therapeutics3.2306 of 5 stars$6.51+1.4%$57.50+783.3%-80.7%$54.80M$145.24M-6.38380Gap DownIMRXImmuneering3.2284 of 5 stars$1.74-3.3%$11.00+532.2%-40.0%$54.03M$320,000.00-0.8860Short Interest ↓Gap DownONCYOncolytics Biotech1.0686 of 5 stars$0.63-0.1%$4.00+535.6%-56.9%$53.81MN/A-2.3330CTMXCytomX Therapeutics3.9984 of 5 stars$0.67+0.4%$5.02+649.9%-77.9%$53.65M$138.10M3.94170PDSBPDS Biotechnology1.5261 of 5 stars$1.37flat$11.67+751.6%-71.1%$52.32MN/A-1.1820Short Interest ↓Gap DownKRONKronos Bio3.6654 of 5 stars$0.87-0.4%$1.63+87.5%-35.1%$52.30M$9.85M-0.61100Short Interest ↓Positive NewsGap DownVRPXVirpax Pharmaceuticals1.4207 of 5 stars$1.94-6.3%$3.00+54.6%-99.7%$51.53MN/A0.007Positive NewsGap DownXFORX4 Pharmaceuticals4.3748 of 5 stars$0.30-4.0%$3.50+1,086.4%-85.4%$51.23M$1.12M-3.2880Analyst RevisionGap DownCTORCitius OncologyN/A$0.71+14.5%$3.00+322.5%N/A$50.80MN/A0.00N/AGap DownVNRXVolitionRx1.728 of 5 stars$0.55-0.4%$3.75+584.3%-29.9%$50.78M$1.29M-1.5280Analyst ForecastGap Down Remove Ads Related Companies and Tools Related Companies Karyopharm Therapeutics Alternatives Immuneering Alternatives Oncolytics Biotech Alternatives CytomX Therapeutics Alternatives PDS Biotechnology Alternatives Kronos Bio Alternatives Virpax Pharmaceuticals Alternatives X4 Pharmaceuticals Alternatives Citius Oncology Alternatives VolitionRx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRKR) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
